Insight Molecular Diagnostics (IMDX) Current Leases (2016 - 2023)

Insight Molecular Diagnostics (IMDX) posted Current Leases of $628000.0 for Q4 2023, up 156.33% sequentially from $245000.0 in Q2 2019.

Insight Molecular Diagnostics (IMDX) Current Leases (2016 - 2023) Analysis & Trends

Insight Molecular Diagnostics has reported Current Leases for 5 years, with the latest figure at $628000.0 in Q4 2023.

Quarterly Current Leases changed N/A year-over-year to $628000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $628000.0 (changed N/A YoY) and the FY2023 annual result came in at $628000.0, changed N/A from the prior year.
Current Leases rose to $628000.0 in Q4 2023 per IMDX's latest filing, from $245000.0 in the prior quarter.
Over five years, Current Leases peaked at $628000.0 in Q4 2023 and troughed at $245000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Thermo Fisher Scientific	213.40 Bn	209.33 Bn	8.34 Bn	-
2	Danaher	139.94 Bn	135.59 Bn	3.61 Bn	-
3	Idexx Laboratories	46.03 Bn	45.83 Bn	779.09 Mn	-
4	Agilent Technologies	39.69 Bn	37.88 Bn	990.00 Mn	-
5	Iqvia Holdings	39.32 Bn	37.24 Bn	1.44 Bn	-
6	Natera	38.47 Bn	37.37 Bn	696.04 Mn	-
7	Illumina	29.98 Bn	28.82 Bn	770.00 Mn	-
8	Mettler Toledo International	28.57 Bn	28.52 Bn	650.22 Mn	-
9	Quest Diagnostics	26.21 Bn	25.58 Bn	1.03 Bn	180.00 Mn
10	Insight Molecular Diagnostics	172.60 Mn	143.67 Mn	15,000.00	-

Download Data